Twist Bioscience Corporation (TWST) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Twist Bioscience Corporation (TWST) Healthcare & Pipeline Overview

Twist Bioscience Corporation leverages a proprietary silicon chip-based DNA synthesis platform to manufacture synthetic DNA products, including genes, antibody libraries, and data storage solutions. The company's innovative approach positions it within the evolving synthetic biology market, supporting advancements in drug discovery, diagnostics, and data archiving through strategic collaborations and technological differentiation.

What Is the Investment Thesis for TWST?

Twist Bioscience Corporation's investment profile is underpinned by its proprietary silicon chip-based DNA synthesis platform, which offers a scalable and precise method for manufacturing synthetic DNA. This technology enables the company to serve diverse, high-growth markets including drug discovery, diagnostics, and data storage. Key value drivers include the expansion of its product portfolio, such as synthetic genes and antibody libraries, which cater to increasing demand in biopharmaceutical research and development. Strategic collaborations, like those with Kyowa Kirin Pharmaceutical Research and Boehringer Ingelheim, validate its technology and provide avenues for future revenue streams through milestone payments and royalties. The company's focus on DNA as a digital data storage medium represents a significant long-term growth catalyst, tapping into a nascent market with substantial potential. Despite a current profit margin of -19.8%, indicating ongoing investment in R&D and scaling operations, the gross margin of 52.1% suggests strong underlying unit economics as production scales. The high beta of 2.23 reflects its growth-oriented nature and sensitivity to market movements, positioning it as a high-potential, albeit higher-risk, opportunity within the synthetic biology sector.

Based on FMP financials and quantitative analysis

TWST Key Highlights

Market Capitalization: $7.81B, reflecting its valuation in the synthetic biology market.

• Gross Margin: 52.1%, indicating strong profitability on its core synthetic DNA product sales before operating expenses.
• Profit Margin: -19.8%, signifying ongoing investments in research, development, and scaling operations, leading to current unprofitability.
• Employee Count: 923 employees, supporting its specialized R&D, manufacturing, and commercial operations.
• Beta: 2.23, suggesting higher volatility compared to the broader market, characteristic of a growth-oriented company in an emerging sector.

Who Are TWST's Competitors?

TWST is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are TWST's Key Strengths?

Proprietary silicon chip-based DNA synthesis platform for high-throughput and precision.

• Diverse product portfolio including synthetic genes, antibody libraries, and DNA data storage.
• Strategic collaboration agreements with leading research and pharmaceutical companies.
• Strong gross margin of 52.1% indicating efficient production economics.

What Are TWST's Weaknesses?

Ongoing negative profit margin of -19.8%, reflecting significant R&D and operational investments.

• High beta of 2.23 suggests stock price volatility and sensitivity to market sentiment.
• Reliance on successful outcomes from research collaborations for future revenue growth.

What Could Drive TWST Stock Higher?

TWST catalyst: Successful advancement or commercialization of products resulting from existing collaboration agreements, such as those with Kyowa Kirin Pharmaceutical Research, Inc. or Boehringer Ingelheim International GmbH, potentially leading to milestone payments or increased product adoption.

• Continued expansion of the company's customer base and increased adoption of its synthetic DNA products across research, drug discovery, and diagnostic applications, driving revenue growth.
• Significant progress or breakthroughs in the development and commercialization of DNA as a digital data storage medium, attracting further investment and demonstrating long-term market potential.
• Introduction of new synthetic DNA-based products or enhancements to its existing platform, broadening its market reach and competitive advantage in the synthetic biology space.

What Are the Key Risks for TWST?

Negative return on equity (-29.9%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $36.5M recently.
• Intense competition within the synthetic biology and gene synthesis markets, which could exert pressure on pricing and market share, impacting profitability.
• The company's current negative profit margin of -19.8% indicates that it is not yet profitable, and there is a risk that it may not achieve sustained profitability in the near to medium term, requiring continued capital investment.
• Technological obsolescence or the emergence of more cost-effective or superior DNA synthesis technologies from competitors could undermine Twist Bioscience's proprietary platform advantage.
• Dependence on the successful execution and commercialization outcomes of its numerous collaboration agreements; failure to achieve anticipated results from these partnerships could impact future revenue streams and market perception.
• High beta of 2.23 suggests that the stock price is highly sensitive to broader market fluctuations and investor sentiment, potentially leading to significant volatility.

What Are the Growth Opportunities for TWST?

• Expansion of Synthetic Gene Market: The market for synthetic genes is continuously expanding, driven by increasing research in gene editing, protein engineering, and vaccine development. Twist Bioscience's ability to manufacture synthetic genes on a silicon chip allows for high-throughput and cost-effective production, catering to this growing demand. As pharmaceutical and academic research intensifies globally, the need for custom synthetic DNA constructs is projected to rise, providing a substantial market opportunity for Twist. The company's platform enables rapid iteration and scale, crucial for accelerating discovery and development timelines across various life science applications, potentially capturing a larger share of this foundational market.
• Growth in Antibody Discovery and Development: Twist Bioscience's proprietary antibody libraries are critical tools for drug discovery, enabling the identification of therapeutic antibodies against various targets. The biopharmaceutical industry's focus on biologics, particularly monoclonal antibodies, continues to grow, with a significant market size for antibody therapeutics. Collaborations, such as the research agreement with Boehringer Ingelheim International GmbH, highlight the value of Twist's libraries in accelerating the drug discovery process. As more pharmaceutical companies seek efficient and diverse antibody discovery platforms, Twist is well-positioned to expand its partnerships and licensing agreements, driving revenue from this high-value segment.
• Advancements in DNA Digital Data Storage: The burgeoning need for long-term, high-density data storage presents a significant, albeit nascent, market opportunity for Twist Bioscience. Utilizing DNA as a digital data storage medium offers unparalleled density and longevity compared to traditional electronic methods. While still in the research and development phase, the potential market size for DNA data storage is immense, driven by the exponential growth of digital information. Twist's core DNA synthesis technology is fundamental to encoding and writing data onto DNA, positioning it as a potential leader in this transformative field as the technology matures and becomes commercially viable over the next decade.
• Strategic Collaboration Expansion in Diagnostics and Sequencing: Twist Bioscience's collaboration agreements with entities like Victorian Clinical Genetic Services, Vivlion GmbH, and Centogene N.V. are focused on developing advanced sequencing tools. The diagnostics market, particularly for genetic testing and precision medicine, is experiencing robust growth. These partnerships allow Twist to integrate its DNA synthesis capabilities into next-generation sequencing workflows, enhancing diagnostic accuracy and efficiency. Expanding these collaborations and developing new tools for sample preparation and target enrichment can unlock significant revenue streams within the clinical and research diagnostics sectors over the mid-term, leveraging its platform's precision and scalability.
• Penetration into Industrial Biotechnology: Synthetic DNA is a foundational component for various applications in industrial biotechnology, including the production of biofuels, enzymes, and novel materials. Twist Bioscience's ability to synthesize custom DNA sequences at scale can enable companies in this sector to optimize biological pathways and engineer microorganisms for specific industrial processes. As industries increasingly adopt sustainable and bio-based manufacturing methods, the demand for synthetic biology tools will rise. Twist can capitalize on this trend by offering its high-quality, custom DNA products to a broader range of industrial clients, fostering innovation and driving growth in this evolving market over the long term.

What Threats Does TWST Face?

• Intense competition from other synthetic biology companies and traditional gene synthesis providers.
• Technological obsolescence if new, more efficient DNA synthesis methods emerge.
• Regulatory changes or intellectual property disputes in the highly innovative biotechnology sector.
• Dependence on R&D success and commercialization of new applications.

What Are TWST's Competitive Advantages?

• Proprietary DNA synthesis platform: The silicon chip-based "writing" of DNA offers a unique, scalable, and precise method, differentiating it from traditional synthesis methods.
• Extensive collaboration network: Partnerships with leading research and pharmaceutical entities validate its technology and integrate its products into critical industry workflows.
• Diverse product portfolio: Offering synthetic genes, sample prep tools, antibody libraries, and DNA data storage addresses multiple high-growth segments within synthetic biology.
• High gross margin: A 52.1% gross margin suggests cost efficiencies and pricing power derived from its advanced manufacturing process.

What Does TWST Do?

Twist Bioscience Corporation, incorporated in 2013 and headquartered in South San Francisco, California, operates as a synthetic biology company focused on the manufacturing and sale of synthetic DNA-based products. The company's foundational innovation is its proprietary DNA synthesis platform, which enables the high-throughput and precise manufacturing of synthetic DNA by "writing" DNA on a silicon chip. This technological advancement allows for the production of a diverse range of synthetic DNA products that serve various applications across the life sciences. Initially established to revolutionize DNA synthesis, Twist Bioscience has evolved to become a key player in providing foundational tools for genetic engineering and drug development. Its product portfolio encompasses synthetic genes, which are essential for research in areas like protein expression and metabolic engineering, as well as tools designed for sample preparation, crucial for next-generation sequencing workflows. Furthermore, the company develops specialized antibody libraries that are instrumental in drug discovery and development efforts, offering a vast repertoire for identifying therapeutic antibodies against a multitude of targets. A forward-looking application of its technology includes the development of DNA as a medium for digital data storage, addressing the growing global need for high-density, long-term data archiving solutions. Twist Bioscience extends its reach through strategic collaboration agreements with various entities, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V, all aimed at developing advanced sequencing tools. Additionally, a research collaboration with Boehringer Ingelheim International GmbH focuses on utilizing Twist's proprietary antibody libraries to discover therapeutic antibodies, solidifying its position within the biopharmaceutical research ecosystem.

What Products and Services Does TWST Offer?

• Manufactures and sells synthetic DNA-based products.
• Utilizes a proprietary DNA synthesis platform that writes DNA on a silicon chip.
• Offers synthetic genes for research and development applications.
• Provides tools for sample preparation, crucial for advanced sequencing.
• Develops antibody libraries for drug discovery and therapeutic development.
• Researches and develops DNA as a medium for digital data storage.
• Engages in collaboration agreements to develop advanced sequencing tools.
• Partners with pharmaceutical companies for therapeutic antibody discovery using its libraries.

How Does TWST Make Money?

• Generates revenue through the direct sale of synthetic DNA-based products, including synthetic genes and sample preparation tools.
• Earns income from licensing its proprietary antibody libraries for drug discovery and development, potentially including milestone payments and royalties from successful therapeutic candidates.
• Forms strategic collaboration agreements with research institutions and companies to develop advanced sequencing tools, which may involve upfront payments, research funding, and future commercialization rights.
• Invests in the long-term potential of DNA digital data storage, anticipating future revenue streams from this emerging technology.

What Industry Does TWST Operate In?

Twist Bioscience operates within the dynamic Healthcare sector, specifically in the Medical - Diagnostics & Research industry, a segment characterized by rapid technological advancements and significant R&D investment. The synthetic biology market, where Twist Bioscience is a key player, is experiencing substantial growth driven by increasing demand for customized biological solutions in drug discovery, advanced diagnostics, and industrial biotechnology. This market is trending towards high-throughput, cost-effective DNA synthesis, a niche where Twist's silicon chip-based platform offers a distinct advantage. The competitive landscape includes traditional gene synthesis providers and other synthetic biology companies, but Twist differentiates itself through its proprietary technology that allows for scalable and precise DNA writing. The company's strategic collaborations with pharmaceutical and diagnostic firms further solidify its position, integrating its technology into critical research and development pipelines across the industry.

Who Are TWST's Key Customers?

• Academic and government research institutions requiring synthetic genes and DNA tools.
• Biopharmaceutical companies engaged in drug discovery and development, utilizing antibody libraries and synthetic genes.
• Diagnostic companies and clinical genetic services developing advanced sequencing applications.
• Companies and organizations exploring DNA as a medium for digital data storage.

Company Profile

Twist Bioscience Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Emily Marine Leproust. TWST has traded publicly since 2018.

Return on equity for Twist Bioscience Corporation stands at -29.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -20.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.67 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.7%, the inverse of the P/E and a quick read on earnings relative to price.

TWST Valuation & Market Position

With a $7.81B market cap, Twist Bioscience Corporation sits in the mid-cap segment of the market. Analyst price targets span from $89.00 to $144.00, with a consensus of $110.78. At the current price of $125.38, that implies roughly 12% downside from the consensus target. Relative to its peer group, TWST's quantitative score of 35/100 is below the peer average of 67/100.

Quarterly Financial Performance: Twist Bioscience Corporation

Revenue for Twist Bioscience Corporation came in at $118.4M during Q3 FY2026, a 6.9% improvement versus the preceding quarter. The company recorded a net loss of $35.1M, with diluted EPS of $-0.56. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, TWST averaged $-0.56 in diluted EPS.

Twist Bioscience Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 18.28 places it in the safe zone, indicating low near-term bankruptcy risk.

Twist Bioscience Corporation has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 2.8% below estimates on average.

Over the past six months, Twist Bioscience Corporation insiders filed 30 SEC Form 4 transactions — 26 sales and 4 purchases. On net that is roughly 268K shares disposed (about $36.5M), a signal worth weighing alongside the fundamentals.

TWST Financials

TWST Latest News

TWST Analyst Consensus

TWST MoonshotScore

Related Investment Themes

TWST Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources